Background {#Sec1}
==========

According to the Global Cancer Statistics 2018, lung cancer is the most common cancer (11.6% of total cancer cases) and the leading cause of cancer deaths (18.4% of the total cancer deaths) worldwide \[[@CR1]\]. Non-small-cell lung cancer (NSCLC), the leading type of lung cancer, accounts for 80% of all cases. Although various therapies, such as surgery, radiotherapy, chemotherapy, targeted therapy, and the rising immunization therapy have emerged, they exhibit limited effects on lung cancer, and the prognosis of patients remains unsatisfactory, with five-year survival rates of 6.3% for small cell lung cancer (SCLC) and 18.2% for NSCLC \[[@CR2]--[@CR4]\]. Compared to treating advanced cancer, prevention is much better. Therefore, it is important to investigate novel prognostic factors to improve treatment therapies.

In the 1960s, Richard B. et al. suggested that platelets were correlated with cancer \[[@CR5]\]. Tumour cells can secrete platelet agonists to induce platelet aggregation, which results in thrombocytosis by producing thrombopoietic cytokines such as interleukin (IL)-1, IL-3, IL-11, and particularly tumour-derived IL-6 \[[@CR6]--[@CR9]\]. Many studies have shown that thrombocytosis plays a role in cancer genesis and development \[[@CR10], [@CR11]\]. Increasing evidence has indicated that platelet count correlates with prognosis in various malignancies, such as lung, renal, gastric, colorectal and hepatocellular cancer and is considered a hallmark of cancer \[[@CR12]--[@CR16]\]. Additionally, the platelet count is convenient to perform, less expensive, and easily available. However, the current opinions about the correlation between platelet count and lung cancer prognosis are controversial. Some studies have identified that platelet count is a poor prognostic factor in NSCLC, while some suggest that platelet count has no association with lung cancer \[[@CR11], [@CR17]--[@CR19]\]. Therefore, we conducted this meta-analysis to further investigate the prognostic value of pretreatment platelet counts for survival in lung cancer patients.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

This meta-analysis was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Additional file [1](#MOESM1){ref-type="media"}). A comprehensive search was conducted by searching databases including the PubMed, EMBASE and Cochrane Library databases using the following terms: ("thrombocytosis" or "thrombocytosis" or "thrombocythemia" or "platelet count" or "blood platelets" or "platelets") and ("lung carcinoma" or "lung cancer" or "lung tumor" or "lung neoplasm") and ("prognosis" or "prognostic" or "survival" or "outcome") up to December 31, 2017.

Selection criteria {#Sec4}
------------------

The inclusion criteria for this meta-analysis were as follows: (1) the diagnosis of lung cancer was confirmed pathologically; (2) platelet count was measured before treatment; (3) hazard ratios (HRs) and their 95% confidence intervals (CIs) for platelet count were reported; (4) the cut-off value of platelet count was reported; and (5) the relationship between overall survival (OS) or disease-free survival (DFS)/progression-free survival (PFS)/time to progression (TTP) and platelet count was evaluated.

Exclusion criteria {#Sec5}
------------------

Articles were excluded if they met the following criteria: (1) articles were reviews, case reports, letters, editorials, or conference abstracts; (2) articles that were not written in English; (3) articles missing key information for evaluating the HR and its 95% CI; (4) studies based on cancer cells or animal models and irrelevant studies; and (5) studies by the same authors with similar or overlapping data. Two reviewers assessed the candidate articles independently. Any disputes were settled through discussion.

Data extraction and quality assessment {#Sec6}
--------------------------------------

Two reviewers independently extracted data from the selected literature and completed quality assessments. The first author name, year of publication, country of origin, number of enrolled patients, tumour type, clinical stage, cut-off value of platelet count, and outcomes were included as publication characteristics. HRs for OS and PFS and their 95% CIs were collected as result data. If the study provided both univariate analysis and multivariate analysis results, we took the results of multivariate analysis because multivariate analyses exclude correlated confounding factors and are more accurate. In addition, only one study (Holgersson G, 2012) categorized platelet count into three groups according to cut-off values (platelet count \< 150, 150 \< platelet count \< 350, and platelet count \> 350), and there were two HRs for OS. We extracted the HR that compared the group with 150 \< platelet count \< 350 and the group with platelet count \> 350. We used the Newcastle-Ottawa Scale (NOS) scoring system to assess the quality of the included articles \[[@CR20]\]. Two reviewers independently evaluated the quality of each included study. The judgement criteria include three aspects of evaluation: selection, comparability, and outcome between the case group and control group. Studies with higher scores had higher quality.

Statistical analysis {#Sec7}
--------------------

The meta-analysis was conducted by STATA 12.0 software (Stata Corp, College Station, TX, USA). HRs and corresponding 95% CIs were used to analyse the association between platelet count and lung cancer. Cochrane's Q test and the I2 statistic were used to evaluate the heterogeneity among the included studies \[[@CR21]\]. I2 \> 50% or *P*-value\< 0.05 indicated heterogeneity in the studies \[[@CR22], [@CR23]\], and a random-effects model was adopted; otherwise, a fixed-effects model was used. Moreover, subgroup analysis was conducted to detect the potential source of heterogeneity. A *P*-value less than 0.05 indicated statistical significance. Publication bias was evaluated by Begg's test and Egger's regression test \[[@CR24]\]. Additionally, sensitivity analysis was performed to check the stability of the results \[[@CR25]\].

Results {#Sec8}
=======

Study characteristics {#Sec9}
---------------------

A flow diagram demonstrating the search procedure is illustrated in Fig. [1](#Fig1){ref-type="fig"}. After the original search, 2395 records were retrieved from the electronic databases. First, we removed duplications, and 1178 records remained. Among them, another 1112 records were also excluded after examining the titles and abstracts. Next, the remaining 66 full texts were assessed for eligibility. Of these, 26 studies were excluded on account of duplicate dates and incomplete data. Ultimately, 40 studies including a total of 16,696 participants met the criteria and were enrolled in this meta-analysis \[[@CR17]--[@CR19], [@CR26]--[@CR60]\]. Fig. 1Flow chart representing the search steps and study selection

The characteristics of the patients included are presented in Table [1](#Tab1){ref-type="table"}. All included studies were published between 1976 and 2017. As shown in Table [1](#Tab1){ref-type="table"}, 40 studies were included in the meta-analysis, 30 studies on NSCLC, 2 studies on SCLC, and 8 studies on all tumour types. Twenty-three studies were performed in Asian populations and 16 in Caucasian populations, while one study did not report the race of the participants. In terms of the cut-off value of platelet count, 8 studies used \< 300 as the cut-off value, 18 studies used 300--400 as the cut-off value, one study did not report the cut-off value of platelet count, and the remaining 13 studies considered ≥400 as the cut-off value. There were 39 studies evaluating the association between OS and platelet count, while 13 studies evaluated the DFS/PFS/TTP outcome. All 40 studies reported the HR and 95% CI directly. Additionally, the quality of the studies was assessed by NOS, as shown in Table [2](#Tab2){ref-type="table"}. Table 1The basic characteristics of included studies in the meta-analysisAuthorYearCountryCasesTumor typeClinical stageCut-off valueOutcomeOSDFS/PFS/TTPU/MHR(95%CI)U/MHR(95%CI)Pedersen LM1996Denmark1115NSCLC+ SLCLI-IV400OSM4.24(1.50--12.72)Cox G2000UK175NSCLCI-IIIA320OSM1.69(1.12--2.56)Suzuki M2002Japan99NSCLCI-IV231OSM3.04(1.08--8.55)Swinson DE2003United Kingdom175NSCLCI-IIIA314OSM1.64(1.13--2.39)Bremnes RM2003Norway436SCLC--150OSM3.10(1.40--7.20)Unsal E2004Turkey58NSCLC+ SLCLI-IV400OSM0.96(0.54--1.72)Aoe K2004Japan611NSCLC+ SLCLI-IV400OSM1.29(1.02--1.64)Prévost S2006Canada120NSCLCNot Report340OSM1.50(1.0--2.30)Tomita M2008Japan240NSCLCI-IV400OSM1.46(1.01--2.01)Gonzalez Barcala FJ2010Spain365NSCLC+ SCLCI-IV258OSM1.15(0.90--1.47)Gonzalez Barcala FJ2010Spain294NSCLC+ SCLCI-IV381OSM1.09(0.82--1.46)Luo J2012USA110NSCLCI-IV300OSM2.86(1.48--5.54)Holgersson G2012Sweden823NSCLCI-IV350OSM1.35(1.12--1.62)Yu D2013China510NSCLCI-III300OS,DFSM1.69(1.01--2.38)M1.57(1.01--2.45)Maráz A2013Hungary398NSCLC+ SLCLI-IV400OSM1.58(1.14--2.18)Kim KH2014Korea854NSCLCIII-IV450OSM1.51(1.14--2.00)Kim M2014Korea199NSCLCI-III400OS,DFSM2.98(1.39--6.37)M2.47(1.22--5.01)Ji Y2014China234NSCLCI300OS,DFSM3.14(1.23--8.03)M5.31(2.75--10.27)Zhu JF2014China275NSCLCIV300OSM1.40(1.00--2.00)Hong X2016China999SCLC--300OS,PFSM1.01(0.87--1.18)M0.91(0.70--1.17)Gotfrit J2016Canada223NSCLCIIIB-IV400OSM1.46(1.03--2.09)Boddu P2016USA571NSCLCI-IV450OSM1.64(1.05--2.55)Liu W2017China1120NSCLCI-IIIA300OS,DFSM1.15(0.96--1.39)M1.17(0.97--1.40)Wang YQ2017China134NSCLCI-IIIA289OS,DFSM2.28(1.43--3.62)U1.63(1.01--2.64)Holgersson G2017Sweden222NSCLCIII350OSM1.66(1.12--2.48)Holgersson G2017Sweden99NSCLCIIIB-IV350OSM1.25(0.71--2.22)Cui MM2017China270NSCLCI-IIINot ReportOSM1.00(1.00--1.01)Ohuchi M2017Japan146NSCLC+ SLCLI-IV244OSM1.88(1.13--3.13)Mandrekar SJ2006Canada+ USA1053NSCLCIIIB-IV375OS,TTPU1.41(1.24--1.60)U1.27(1.11--1.45)Altiay G2007Turkey78NSCLC+ SLCLIII-IV400OSU2.33(1.27--4.26)Qiu MZ2010China430NSCLCI-IV400OSU1.09(0.60--1.98)Liu HB2013China883NSCLCI-IV300OSU1.30(1.02--1.66)Du G2013China258NSCLCIIIA-IV400OS,PFSU4.15(3.09--5.59)U3.47(2.60--4.65)Zhang T2014China400NSCLCI-II190OS,DFSU1.47(0.88--2.45)U1.57(1.01--2.45)Wu G2015China366NSCLCIII-IV117.5OS,PFSU1.22(0.90--1.65)U1.25(0.92--1.69)Zhang H2015China1238NSCLCI-IIIA300OS,DFSU1.38(1.17--1.63)U1.38(1.16--1.63)Zhang W2015China308NSCLCI-IV300OSU1.67(1.23--2.27)Gao L2017China546NSCLCI-IIIA300OS,DFSU1.72(1.35--2.19)U1.70(1.33--2.17)Li Y2014China126NSCLCIII-IV200PFSM1.69(1.16--2.46)Lee S2017Korea135NSCLCIIIB-IV400OSU1.49(0.80--2.78)*NSCLC* Non-small cell lung cancer, *SCLC* Small cell lung cancer, *OS* Overall survival, *DFS* Disease-free survival, *PFS* Progress-free survival, *TTP* Time to progress, *HR* Hazard ratio, *CI* Confidence interval *M* Multivariate analysis, *U* Univariate analysis Table 2Quality assessment of containing studies using the Newcastle-Ottawa ScaleStudySelectionComparabilityOutcomeTotal scorePedersen LM4138Cox G4228Suzuki M4026Swinson DE4026Bremnes RM4026Unsal E4127Aoe K4026Mandrekar SJ4127Prévost S4026Altiay G4026Tomita M4228Qiu MZ4226Gonzalez Barcala FJ4228Gonzalez Barcala FJ4228Luo J4127Holgersson G4127Yu D4228Liu HB4026Maráz A4026Du G4127Kim KH4217Kim M4228Zhang T4037Ji Y4127Zhu JF4228Wu G4026Zhang H4127Zhang W4037Hong X4026Gotfrit J4026Boddu P4127Gao L4239Liu W4228Wang YQ4127Lee S4026Holgersson G4026Holgersson G4026Cui MM4037Ohuchi M4026Li Y4217

Meta-analysis {#Sec10}
-------------

### OS {#Sec11}

There were 39 studies including 16,570 patients providing data on the prognostic role of platelet count for OS in lung cancer. The results indicate that elevated platelet counts were associated with poorer OS in lung cancer patients (HR = 1.54, 95% CI: 1.37--1.72, *P* \< 0.001, Fig. [2](#Fig2){ref-type="fig"}a). Then, we conducted subgroup analysis for further investigation, and the results are summarized in Table [3](#Tab3){ref-type="table"}. In the subgroup stratified by ethnicity, we observed that elevated platelet counts predicted poor OS in Asian populations (HR = 1.54, 95% CI: 1.32--1.8, *P* \< 0.001), while that in non-Asian populations had no significance (*P* = 0.063). Based on clinical stage, a significant association between elevated platelet counts and OS was found in stage I-III (HR = 1.52, 95% CI: 1.22--1.89, *P* \< 0.001) and stage \>III (HR = 1.7, 95% CI: 1.26--2.29, *P* \< 0.001). An obvious association between elevated platelet counts and OS was observed when integrating the data from 28 studies in which OS was evaluated with multivariate analyses (HR = 1.47, 95% CI: 1.31--1.66, *P* \< 0.001). In terms of the cut-off value, the subgroup analysis confirmed that increased platelet counts were a negative predictor in patients with cut-off values\< 300 (HR = 1.64, 95% CI: 1.25--2.15, *P* \< 0.05) and with cut-off values\> 400 (HR = 1.73, 95% CI: 1.35--2.21, *P* \< 0.001) Additionally, high platelet counts still predicted worse OS in patients with lung cancer, regardless of the subtype of lung cancer (SCLC or NSCLC). Fig. 2Forest plot showing the HRs with 95% CIs for the association between elevated platelet counts and OS (**a**) or DFS/PFS/TTP (**b**) Table 3The results of subgroup analysis in meta-analysis of OS and DFS/PFS/TTPSubgroupNo. of studiesHR (95% CI)PHeterogeneityModel usedI^2^P~h~OSAnalysis of variableMultivariate281.47(1.31--1.66)\< 0.00180.60%\< 0.001RandomUnivariate111.62(1.33--1.99)\< 0.00181.70%\< 0.001RandomEthnicityAsian221.54(1.32--1.80)\< 0.00189.80%\< 0.001Randomnon-Asian171.42(1.32--1.53)0.06337.00%0.063FixedTumor stageI-III91.52(1.22--1.89)\< 0.00189.00%\< 0.001RandomIII-IV81.70(1.26--2.29)\< 0.00185.80%\< 0.001RandomI-IV151.37(1.26--1.49)0.06638.20%0.066FixedHistologyNSCLC291.58(1.38--1.82)\< 0.00189.80%\< 0.001RandomSCLC21.64(0.55--4.87)0.00885.60%0.008RandomNSCLC+SCLC81.39(1.14--1.70)0.03653.40%0.036Randomcut-off value\<300 × 10\^9/L71.64(1.25--2.15)0.02458.80%0.024Random300 × 10\^9/L ≤ cut-off value\<400 × 10\^9/L181.40(1.27--1.55)0.00255.40%0.002Random≥400 × 10\^9/L131.73(1.35--2.21)\< 0.00177.90%\< 0.001RandomQuality score\> 6231.59(1.36--1.85)\< 0.00191.20%\< 0.001Random≤6161.30(1.19--1.41)0.01548.60%0.015FixedDFS/PFS/TTPAnalysis of variableMultivariate71.66(1.14--2.42)\< 0.00184.40%\< 0.001RandomUnivariate61.63(1.28--2.09)\< 0.00185.50%\< 0.001RandomEthnicityAsian121.68(1.33--2.12)\< 0.00185.10%\< 0.001Randomnon-Asian1----------Tumor stageI-III61.40(1.26--1.55)0.09746.30%0.097FixedIII-IV41.74(1.09--2.78)\< 0.00192.50%\< 0.001RandomHistologyNSCLC121.71(1.40--2.09)\< 0.00183.00%\< 0.001RandomSCLC1----------cut-off value\<300 × 10\^9/L41.47(1.21--1.78)0.5840.00%0.584Fixed300 × 10\^9/L ≤ cut-off value\<400 × 10\^9/L71.42(1.15--1.74)\< 0.00181.40%\< 0.001Random≥400 × 10\^9/L23.30(2.52--4.32)0.3830.00%0.383FixedQuality score\> 6111.77(1.42--2.20)\< 0.00184.30%\< 0.001Random≤621.04(0.85--1.26)0.1140.5990.114Fixed*OS* Overall survival, *DFS* Disease-free survival, *PFS* Progress-free survival, *TTP* Time to progress, *NSCLC* Non-small cell lung cancer, *SCLC* Small cell lung cancer, *HR* Hazard ratio, *CI* Confidence interval

### DFS/PFS/TTP {#Sec12}

The meta-analysis of DFS/PFS/TTP, which contained 13 studies with 7183 patients, indicated that cancer patients with high platelet counts had significantly shorter DFS/PFS/TTP than those with low platelet counts (HR = 1.62, 95% CI: 1.33--1.98, *P* \< 0.001, Fig. [2](#Fig2){ref-type="fig"}b). A random-effects model was used. Subgroup analysis was performed, and the results are shown in Table [3](#Tab3){ref-type="table"}. The results suggested that in the subgroup analysis, elevated platelet count was a negative predictor in the Asian population subgroup (*P* \< 0.001), multivariate analysis subgroup (*P* \< 0.001), stage III-IV disease subgroup (*P* \< 0.001), and 300 ≤ cut-off value\< 400 subgroup (*P* \< 0.001).

In the following four subgroups, patients with elevated pretreatment platelet counts had similar DFS/PFS/TTP compared with patients with normal platelet counts: stage I-III disease subgroup (*P* = 0.097), studies with a quality score ≤ 6 (*P* = 0.114), platelet count \> 400 subgroup (*P* = 0.383), and platelet count \< 300 subgroup (*P* = 0.584).

### Publication bias and sensitivity analysis {#Sec13}

As shown in Fig. [3](#Fig3){ref-type="fig"}, the funnel plot was symmetrical. Based on Begg's test (*P* = 0.866) and Egger's regression test (*P* = 0.376), no significant publication bias was found. Fig. 3Begg's funnel plots and Egger's test evaluating possible publication bias for (**a**) OS; (**b**) DFS/PFS/TTP

Furthermore, we performed sensitivity analysis to evaluate the reliability of our results. The corresponding pooled HR values were not significantly impacted, indicating the robustness of our conclusions (Fig. [4](#Fig4){ref-type="fig"}). Fig. 4Sensitivity to the relationship between elevated platelet counts and OS (**a**) or DFS/PFS/TTP (**b**)

Discussion {#Sec14}
==========

Cancer is undoubtedly one of the most serious public health problems. In the past few years, antidiuretic hormone (ADH), tumour necrosis factor alpha (TNF-α), NF-κB/p65, COX-2 and thyroid transcription factor-1 (TTF-1) have been reported to be associated with the prognosis of lung cancer. However, their specificity and sensitivity in prognosis are still not satisfactory. Therefore, the exploration of new lung cancer prognostic markers is of great significance for clinicians to take targeted measures and improve the prognosis of patients.

In recent years, it has been observed that some systemic inflammation indicators, such as the neutrophil-to-lymphocyte ratio (NLR) \[[@CR61]\], platelet-to-lymphocyte ratio (PLR) \[[@CR62]\], Glasgow prognostic score (GPS) \[[@CR63]\], Prognostic Index (PI) and Prognostic Nutritional Index (PNI) \[[@CR64]\], play important roles in tumorigenesis and development and can be considered predictors of prognosis. In the 1960s, Richard B observed that the platelet count is elevated in patients with cancers compared to those with nonmalignant diseases \[[@CR5]\]. Accumulating evidence suggests that elevated platelet counts are associated with various cancers, such as colorectal cancer, lung cancer, and endometrial carcinoma \[[@CR12], [@CR65], [@CR66]\]. Platelets sustain proliferative signalling, resist cell death, and induce tumour angiogenesis \[[@CR67]\]. Additionally, platelets activate the TGF-β/Smad and NF-κB pathways, further promoting tumour migration and invasion \[[@CR68]\]. Moreover, as immune cells \[[@CR69]\], platelets release TGF-β, reducing the expression of NKG2D and weakening the role of natural killer (NK) cells \[[@CR70]\]. Platelets could be a prognostic predictor used in the clinic. Recently, several studies confirming the prognostic value of platelet count in lung cancer have been carried out; however, the results were inconsistent. Therefore, we conducted a meta-analysis to determine the precise role of platelet counts in lung cancer.

We combined the outcomes of 40 studies with 16,696 patients, suggesting that elevated platelet counts are a poor predictor of OS and DFS/PFS/TTP in lung cancer patients. In our subgroup analysis, elevated platelet counts were significantly associated with poor OS and DFS/PFS/TTP in diverse subgroups, such as Asian populations, tumour stages I-III, tumour stages III-IV, and studies with quality scores \> 6. However, the cut-off value of the platelet count was variable. We found that elevated platelet counts were significantly associated with poor OS and DFS/PFS/TTP when the cut-off value was between 300 and 400, while the cut-off value of \> 400 did not have a relationship with poor DFS/PFS/TTP. Overall, the cut-off value of plate count between 300 and 400 can separate patients well for OS and DFS/PFS/TTP and should be used as a prognostic biomarker in clinical use, which is more precise than the findings of the previous meta-analysis \[[@CR71]\]. Compared to the previous meta-analysis \[[@CR71]\], our results are more comprehensive and accurate. On the one hand, we included 40 articles in the meta-analysis, which included more new and important studies, increasing the analytical capability of the analysis. On the other hand, a more detailed subgroup analysis was performed. In addition to race and the cut-off value of platelet count, we also investigated the prognostic role of platelet count in different tumour stages, histology and quality scores. Additionally, we discussed the association between platelets and OS as well as DFS/PFS/TTP, while the previous meta-analysis studied only the significance in OS.

However, there are some limitations of this study that deserve to be mentioned. First, the studies included in our meta-analysis are retrospective studies and are therefore more likely to have selection bias. Second, although the publication bias and sensitivity analyses confirmed the credibility of our analysis, heterogeneity still existed in this meta-analysis due to several factors, such as patient characteristics, sample size, and adjuvant therapy, which were not included in our analysis. Moreover, the cut-off value for definition of the elevated platelet counts differed among the studies. Most of the studies used 300--400 as the cut-off value, while several others used \< 300 or \> 400 as the cut-off value of platelet count to assess the prognosis, which might lead to between-study heterogeneity. Last, platelet count could be affected by several factors, such as thrombosis, hypertension, splenic diseases, blood coagulation disorders, myeloproliferative disease, infection and drugs. Therefore, platelet count cannot play a prognostic role if patients have these diseases mentioned above.

Conclusions {#Sec15}
===========

In conclusion, our meta-analysis revealed that elevated pretreatment platelet counts are related to poor OS and DFS/PFS/TTP in lung cancer patients and are an independent prognostic predictor of lung cancer patients. Considering the limitations, large-scale prospective studies and a validation study are warranted to confirm our results.
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 {#Sec16}

**Additional file 1.** PRISMA checklist.

DFS

:   Disease-free survival

PFS

:   Progression-free survival

TTP

:   Time to progression

OS

:   Overall survival

HR

:   Hazard ratio

CIs

:   Confidence intervals

NSCLC

:   Non-small-cell lung cancer

SCLC

:   Small cell lung cancer

NOS

:   Newcastle-Ottawa Scale

NLR

:   Neutrophil-to-lymphocyte ratio

PLR

:   Platelet-to-lymphocyte ratio

GPS

:   Glasgow prognostic score

PI

:   Prognostic Index

PNI

:   Prognostic Nutritional Index
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